Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
Chr del(17p)
Cancer:
Chronic Lymphocytic Leukemia
Drug:
Gazyva (obinutuzumab)
(
CD20 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: CLL/SLL With del(17p)/TP53 Mutation...Useful in Certain Circumstances...Obinutuzumab…
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login